Active Biotech AB (publ)
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more
Market Cap & Net Worth: Active Biotech AB (publ) (BTPC)
Active Biotech AB (publ) (F:BTPC) has a market capitalization of $9.74 Million (€9.49 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #32509 globally and #3637 in its home market, demonstrating a -5.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Active Biotech AB (publ)'s stock price €0.00 by its total outstanding shares 2636067170 (2.64 Billion).
Active Biotech AB (publ) Market Cap History: 2015 to 2026
Active Biotech AB (publ)'s market capitalization history from 2015 to 2026. Data shows change from $4.09 Billion to $9.74 Million (-42.04% CAGR).
Active Biotech AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Active Biotech AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.47x
Active Biotech AB (publ)'s market cap is 36.47 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.09 Billion | $16.27 Million | -$193.53 Million | 251.05x | N/A |
| 2016 | $2.88 Billion | $19.04 Million | -$59.58 Million | 151.05x | N/A |
| 2017 | $411.29 Million | $20.25 Million | -$108.79 Million | 20.31x | N/A |
| 2018 | $763.05 Million | $20.05 Million | -$36.88 Million | 38.06x | N/A |
| 2019 | $456.75 Million | $8.43 Million | -$34.13 Million | 54.21x | N/A |
| 2020 | $541.17 Million | $6.72 Million | -$32.24 Million | 80.47x | N/A |
| 2021 | $227.02 Million | $6.22 Million | -$49.83 Million | 36.47x | N/A |
Competitor Companies of BTPC by Market Capitalization
Companies near Active Biotech AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Active Biotech AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Active Biotech AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, Active Biotech AB (publ)'s market cap moved from $4.09 Billion to $ 9.74 Million, with a yearly change of -42.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €9.74 Million | -18.18% |
| 2025 | €11.91 Million | -69.66% |
| 2024 | €39.23 Million | -51.51% |
| 2023 | €80.90 Million | -64.82% |
| 2022 | €230.00 Million | +1.31% |
| 2021 | €227.02 Million | -58.05% |
| 2020 | €541.17 Million | +18.48% |
| 2019 | €456.75 Million | -40.14% |
| 2018 | €763.05 Million | +85.53% |
| 2017 | €411.29 Million | -85.70% |
| 2016 | €2.88 Billion | -29.60% |
| 2015 | €4.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Active Biotech AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.74 Million USD |
| MoneyControl | $9.74 Million USD |
| MarketWatch | $9.74 Million USD |
| marketcap.company | $9.74 Million USD |
| Reuters | $9.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.